Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: A Placebo Controlled Study of Colesevelam in Fecal Incontinence
Brief Summary: Fecal incontinence (FI) is a common symptom that can significantly impair quality of life. There is very limited, mostly uncontrolled, evidence to support the approaches currently used to manage FI. The alpha-2 adrenergic agonist clonidine decreased the frequency of loose stools in FI patients with diarrhea. Among patients with diarrhea, clonidine decreased the proportion of days with FI; however results were not statistically significant. Uncontrolled studies suggest that the bile acid binding resin colesevelam also increased stool consistency in patients with functional diarrhea. In this study, the investigators propose to compare the effects of a combination of colesevelam and clonidine to placebo on bowel symptoms in patients with urge or combined type of FI. The investigators hypothesis is that combination treatment with clonidine and colesevelam is better than placebo in reducing stool frequency and rectal urgency in FI.